Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 [Yahoo! Finance]
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
Company Research
Source: Yahoo! Finance
ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024 Toronto, Ontario--(Newsfile Corp. - May 14, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis ("ARCHER") was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal - the annual congress of the Heart Failure Association of the European Society o
Show less
Read more
Impact Snapshot
Event Time:
CRDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDL alerts
High impacting Cardiol Therapeutics Inc. - Class A Common Shares news events
Weekly update
A roundup of the hottest topics
CRDL
News
- Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? [Yahoo! Finance]Yahoo! Finance
- US producer prices unchanged in September [Yahoo! Finance Canada]Yahoo! Finance Canada
- Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares [Yahoo! Finance]Yahoo! Finance
- Terry Lynch Joins BioNxt as Capital Markets Advisor [Yahoo! Finance]Yahoo! Finance
CRDL
Analyst Actions
- 10/24/24 - HC Wainwright
CRDL
Sec Filings
- 10/22/24 - Form 6-K
- 10/11/24 - Form 6-K
- 10/10/24 - Form 6-K
- CRDL's page on the SEC website